In last trading session, Nektar Therapeutics (NASDAQ:NKTR) saw 1.85 million shares changing hands with its beta currently measuring 0.61. Company’s recent per share price level of $1.37 trading at -$0.02 or -1.44% at ring of the bell on the day assigns it a market valuation of $252.19M. That closing price of NKTR’s stock is at a discount of -40.88% from its 52-week high price of $1.93 and is indicating a premium of 70.07% from its 52-week low price of $0.41. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.94 million shares which gives us an average trading volume of 1.18 million if we extend that period to 3-months.

For Nektar Therapeutics (NKTR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.71. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.21 in the current quarter.

Nektar Therapeutics (NASDAQ:NKTR) trade information

Upright in the red during last session for losing -1.44%, in the last five days NKTR remained trading in the green while hitting it’s week-highest on Wednesday, 11/06/24 when the stock touched $1.37 price level, adding 6.8% to its value on the day. Nektar Therapeutics’s shares saw a change of 142.48% in year-to-date performance and have moved 15.13% in past 5-day. Nektar Therapeutics (NASDAQ:NKTR) showed a performance of 5.38% in past 30-days. Number of shares sold short was 6.04 million shares which calculate 5.64 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 18.5 to the stock, which implies a rise of 92.59% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 24. It follows that stock’s current price would drop -337.96% in reaching the projected high whereas dropping to the targeted low would mean a loss of -337.96% for stock’s current value.

Nektar Therapeutics (NKTR) estimates and forecasts

Statistics highlight that Nektar Therapeutics is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -14.38% of value to its shares in past 6 months, showing an annual growth rate of 41.38% while that of industry is 18.90. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -10.60% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 18.28M for the same. And 7 analysts are in estimates of company making revenue of 17.87M in the next quarter. Company posted 24.14M and 23.89M of sales in current and next quarters respectively a year earlier.

In 2024, company’s earnings growth rate is likely to be around 44.88% while estimates for its earnings growth in next 5 years are of -7.30%.

Nektar Therapeutics (NASDAQ:NKTR)’s Major holders

Insiders are in possession of 1.06% of company’s total shares while institution are holding 73.55 percent of that, with stock having share float percentage of 74.33%. Investors also watch the number of corporate investors in a company very closely, which is 73.55% institutions for Nektar Therapeutics that are currently holding shares of the company. DEEP TRACK CAPITAL, LP is the top institutional holder at NKTR for having 17.88 million shares of worth $22.17 million. And as of 2024-06-30, it was holding 9.1789 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 15.16 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.7823 of outstanding shares, having a total worth of $18.79 million.